Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

RemeGen Co: Clinical Trials & FDA Approval Profile

RemeGen Co (Global / Institutional) sponsors 61 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 27 active protocols (20 recruiting now), 16 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.6%
Median Closed Enrollment vs National (145 pts)44 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for RemeGen Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)61
Active Pipeline (Recruiting Now)27 (20)
Completed vs Stopped Early16 / 4 (6.6%)
Median Closed Actual Enrollment44 participants
Physical Hospital Site Disclosure99.1% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With RemeGen Co
Hospital Research SiteLocationShared Protocols
Beijing Cancer HospitalBeijing, Beijing Municipality15
Hunan Cancer HospitalChangsha, Hunan13
The first affiliated hospital of Zhengzhou UniversityZhengzhou, Henan13

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by RemeGen Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07416474RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (Phase IIIRECRUITING
NCT06155396A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With RPhase IIRECRUITING
NCT07462143A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal CancerPhase II/IIIRECRUITING
NCT06962865A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable LPhase IIRECRUITING
NCT06221748DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After ProgressionPhase II/IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the RemeGen Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI